Your browser doesn't support javascript.
loading
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies.
Wesevich, Austin; Goldstein, Daniel A; Paydary, Koosha; Peer, Cody J; Figg, William D; Ratain, Mark J.
Afiliación
  • Wesevich A; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
  • Goldstein DA; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Paydary K; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
  • Peer CJ; Clalit Health Service, Tel Aviv, Israel.
  • Figg WD; Optimal Cancer Care Alliance, Chicago, IL, USA.
  • Ratain MJ; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
Br J Cancer ; 129(9): 1389-1396, 2023 10.
Article en En | MEDLINE | ID: mdl-37542109
Immune checkpoint inhibitors (ICIs) are approved for the treatment of a variety of cancer types. The doses of these drugs, though approved by the Food and Drug Administration (FDA), have never been optimised, likely leading to significantly higher doses than required for optimal efficacy. Dose optimisation would hypothetically decrease the risk, severity, and duration of immune-related adverse events, as well as provide an opportunity to reduce costs through interventional pharmacoeconomic strategies such as off-label dose reductions or less frequent dosing. We summarise existing evidence for ICI dose optimisation to advocate for the role of interventional pharmacoeconomics.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Economía Farmacéutica / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Health_economic_evaluation Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Br J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Economía Farmacéutica / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Health_economic_evaluation Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Br J Cancer Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos